Additional file 2: of Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Additional file 1: of Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria

Brittany Dennis (3486200)
Pavel Roshanov (3486203)
Leen Naji (3486209)
Monica Bawor (516749)
James Paul (219464)
Carolyn Plater (3486206)
Guillaume Pare (3486221)
Andrew Worster (3486215)
Michael Varenbut (3486212)
Jeff Daiter (3486218)
David Marsh (203655)
Dipika Desai (347048)
Zainab Samaan (516751)
Lehana Thabane (17078)

October 2015

Table outlining description of studies included in the systematic review. (PDF 262 kb

Additional file 2: of Optimising first- and second-line treatment strategies for untreated major depressive disorder â the SUNâşD study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Tadashi Kato (1538845)
Toshi Furukawa (5500829)
Akio Mantani (5500817)
Kenâichi Kurata (5500892)
Hajime Kubouchi (5500811)
Susumu Hirota (5500796)
Hirotoshi Sato (117839)
Kazuyuki Sugishita (5500823)
Bun Chino (5500832)
Kahori Itoh (5500826)
Yoshio Ikeda (260838)
Yoshihiro Shinagawa (5500805)
Masaki Kondo (197045)
Yasumasa Okamoto (82701)
Hirokazu Fujita (5500799)
Motomu Suga (219637)
Shingo Yasumoto (5500814)
Naohisa Tsujino (5500802)
Takeshi Inoue (208656)
Noboru Fujise (3164064)
Tatsuo Akechi (417303)
Mitsuhiko Yamada (113758)
Shinji Shimodera (306974)
Norio Watanabe (39913)
Masatoshi Inagaki (553137)
Kazuhira Miki (5500808)
Yusuke Ogawa (5500835)
Nozomi Takeshima (4433596)
Yu Hayasaka (4433599)
Aran Tajika (5500793)
Kiyomi Shinohara (4433602)
Naohiro Yonemoto (468815)
Shiro Tanaka (307051)
Qi Zhou (7408)
Gordon Guyatt (56595)

July 2018

Figure S1. Schedule of the assessments. Table S1. Incidence of suicidality, manic switches or any se...

Additional file 1: of Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study

Zheng Tong (668206)
Fangzhou Li (3707971)
Yusuke Ogawa (5500835)
Norio Watanabe (39913)
Toshi Furukawa (5500829)

November 2018

Appendix 1 Free text words for searching. Appendix 2 Tool for assessing risk of bias. Appendix 3 Tel...

Additional file 1: of Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Constance Zou (4256887)
Jessica Becker (3503441)
Adam Phillips (4256890)
James Garritano (5890505)
Harlan Krumholz (3401270)
Jennifer Miller (810455)
Joseph Ross (3435704)

October 2018

Additional information for the Methods section. Details on how the trial results were categorized as...

Additional file 3: of Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

Joshua Wallach (4741575)
Oriana Ciani (4485976)
Alison Pease (4991474)
Gregg S. Gonsalves (731654)
Harlan Krumholz (3401270)
Rod Taylor (25312)
Joseph Ross (3435704)

March 2018

Table S1. Pivotal trials with at least one postapproval trial with a patient-relevant outcome. (XLSX...

Additional file 1: of Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Douglas Johnson (302588)
Ali Manouchehri (6727304)
Alexandra Haugh (6727307)
Henry Quach (6727310)
Justin Balko (4424944)
Benedicte Lebrun-Vignes (6727313)
Andrew Mammen (3855379)
Javid Moslehi (5203835)
Joe-Elie Salem (4351000)

May 2019

Table S1. Neuro-psychiatric adverse events grouping as a function of Medical Dictionary for Regulato...

Additional file 2: Table S1. of Association of the FDA Amendment Act with trial registration, publication, and outcome reporting

Adam Phillips (4256890)
Nihar Desai (765329)
Harlan Krumholz (3401270)
Constance Zou (4256887)
Jennifer Miller (810455)
Joseph Ross (3435704)

July 2017

Presenting the clinical trials supporting FDA approvals of drugs in cardiovascular disease and diabe...

Additional file 2: of A comparison of quality of abstracts of systematic reviews including meta-analysis of randomized controlled trials in high-impact general medicine journals before and after the publication of PRISMA extension for abstracts: a systematic review and meta-analysis

Jean Bigna (3412478)
Lewis Um (3412484)
Jobert Nansseu (3412481)

October 2016

Search strategy for systematic reviews including meta-analysis of randomized controlled trials publi...

Additional file 1: of Antidepressant outcomes of high-frequency repetitive transcranial magnetic stimulation (rTMS) with F8-coil and deep transcranial magnetic stimulation (DTMS) with H1-coil in major depression: a systematic review and meta-analysis

Helena Gellersen (6678581)
Karina Kedzior (6678584)

May 2019

Figure S1. Depression severity: outlier analysis and one-study removed analysis. Figure S2. Depressi...

Additional file 1: of A cognitive forcing tool to mitigate cognitive bias â a randomised control trial

Eoin OâSullivan (6188645)
Susie Schofield (3567665)

January 2019

Confirmed Bias in Clinical Medicine. A list of cognitive bias that has been specifically identified ...

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease: a meta-analysis of randomized controlled trials

Abdelrahman Abushouk (3904879)
Ahmed Elmaraezy (3500438)
Amro Aglan (3904891)
Reham Salama (3904894)
Samar Fouda (3904882)
Rana Fouda (3904885)
Ammar AlSafadi (3904888)

April 2017

Shows the authorsâ judgements for risk of bias assessment domains with supporting reasons. (DOCX 2...

Additional file 2: of Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis

Myrlene Aigbogun (6413417)
Robert Stellhorn (6413420)
Ann Hartry (5165477)
Ross Baker (1304541)
Howard Fillit (5165483)

March 2019

TableS2. All medications including antipsychotics and anti-dementia treatments collected for patient...

Additional file 2: of Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders

Gaurav Kaushik (1309584)
Yu Xia (8822)
Luobin Yang (3564683)
Michael Thomas (377350)

June 2016

Complete data of gene sets analyzed. Excel file containing a complete data of all gene sets (neurona...

Additional file 1: of Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia

Stanley Caroff (5783888)
Fan Mu (5783894)
Rajeev Ayyagari (829202)
Traci Schilling (5783900)
Victor Abler (4810095)
Benjamin Carroll (5783903)

September 2018

Table S1. Diagnostic Codes for Schizophrenia and Psychiatric Relapse. Listing of ICD-9 and ICD-10 co...

Additional file 2: of A cognitive forcing tool to mitigate cognitive bias â a randomised control trial

Eoin OâSullivan (6188645)
Susie Schofield (3567665)

January 2019

The clinical scenarios. Clinical vignettes designed to increase the chance of specific cognitive bia...

Additional file 1: of Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria

Brittany Dennis (3486200)
Pavel Roshanov (3486203)
Leen Naji (3486209)
Monica Bawor (516749)
James Paul (219464)
Carolyn Plater (3486206)
Guillaume Pare (3486221)
Andrew Worster (3486215)
Michael Varenbut (3486212)
Jeff Daiter (3486218)
David Marsh (203655)
Dipika Desai (347048)
Zainab Samaan (516751)
Lehana Thabane (17078)

October 2015

Table outlining description of studies included in the systematic review. (PDF 262 kb

Additional file 2: of Optimising first- and second-line treatment strategies for untreated major depressive disorder â the SUNâşD study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Tadashi Kato (1538845)
Toshi Furukawa (5500829)
Akio Mantani (5500817)
Kenâichi Kurata (5500892)
Hajime Kubouchi (5500811)
Susumu Hirota (5500796)
Hirotoshi Sato (117839)
Kazuyuki Sugishita (5500823)
Bun Chino (5500832)
Kahori Itoh (5500826)
Yoshio Ikeda (260838)
Yoshihiro Shinagawa (5500805)
Masaki Kondo (197045)
Yasumasa Okamoto (82701)
Hirokazu Fujita (5500799)
Motomu Suga (219637)
Shingo Yasumoto (5500814)
Naohisa Tsujino (5500802)
Takeshi Inoue (208656)
Noboru Fujise (3164064)
Tatsuo Akechi (417303)
Mitsuhiko Yamada (113758)
Shinji Shimodera (306974)
Norio Watanabe (39913)
Masatoshi Inagaki (553137)
Kazuhira Miki (5500808)
Yusuke Ogawa (5500835)
Nozomi Takeshima (4433596)
Yu Hayasaka (4433599)
Aran Tajika (5500793)
Kiyomi Shinohara (4433602)
Naohiro Yonemoto (468815)
Shiro Tanaka (307051)
Qi Zhou (7408)
Gordon Guyatt (56595)

July 2018

Figure S1. Schedule of the assessments. Table S1. Incidence of suicidality, manic switches or any se...

Additional file 1: of Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study

Zheng Tong (668206)
Fangzhou Li (3707971)
Yusuke Ogawa (5500835)
Norio Watanabe (39913)
Toshi Furukawa (5500829)

November 2018

Appendix 1 Free text words for searching. Appendix 2 Tool for assessing risk of bias. Appendix 3 Tel...

Additional file 1: of Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Constance Zou (4256887)
Jessica Becker (3503441)
Adam Phillips (4256890)
James Garritano (5890505)
Harlan Krumholz (3401270)
Jennifer Miller (810455)
Joseph Ross (3435704)

October 2018

Additional information for the Methods section. Details on how the trial results were categorized as...

Additional file 3: of Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

Joshua Wallach (4741575)
Oriana Ciani (4485976)
Alison Pease (4991474)
Gregg S. Gonsalves (731654)
Harlan Krumholz (3401270)
Rod Taylor (25312)
Joseph Ross (3435704)

March 2018

Table S1. Pivotal trials with at least one postapproval trial with a patient-relevant outcome. (XLSX...

Additional file 1: of Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Douglas Johnson (302588)
Ali Manouchehri (6727304)
Alexandra Haugh (6727307)
Henry Quach (6727310)
Justin Balko (4424944)
Benedicte Lebrun-Vignes (6727313)
Andrew Mammen (3855379)
Javid Moslehi (5203835)
Joe-Elie Salem (4351000)

May 2019

Table S1. Neuro-psychiatric adverse events grouping as a function of Medical Dictionary for Regulato...

Additional file 2: Table S1. of Association of the FDA Amendment Act with trial registration, publication, and outcome reporting

Adam Phillips (4256890)
Nihar Desai (765329)
Harlan Krumholz (3401270)
Constance Zou (4256887)
Jennifer Miller (810455)
Joseph Ross (3435704)

July 2017

Presenting the clinical trials supporting FDA approvals of drugs in cardiovascular disease and diabe...

Additional file 2: of A comparison of quality of abstracts of systematic reviews including meta-analysis of randomized controlled trials in high-impact general medicine journals before and after the publication of PRISMA extension for abstracts: a systematic review and meta-analysis

Jean Bigna (3412478)
Lewis Um (3412484)
Jobert Nansseu (3412481)

October 2016

Search strategy for systematic reviews including meta-analysis of randomized controlled trials publi...

Additional file 1: of Antidepressant outcomes of high-frequency repetitive transcranial magnetic stimulation (rTMS) with F8-coil and deep transcranial magnetic stimulation (DTMS) with H1-coil in major depression: a systematic review and meta-analysis

Helena Gellersen (6678581)
Karina Kedzior (6678584)

May 2019

Figure S1. Depression severity: outlier analysis and one-study removed analysis. Figure S2. Depressi...

Additional file 1: of A cognitive forcing tool to mitigate cognitive bias â a randomised control trial

Eoin OâSullivan (6188645)
Susie Schofield (3567665)

January 2019

Confirmed Bias in Clinical Medicine. A list of cognitive bias that has been specifically identified ...

Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâs disease: a meta-analysis of randomized controlled trials

Abdelrahman Abushouk (3904879)
Ahmed Elmaraezy (3500438)
Amro Aglan (3904891)
Reham Salama (3904894)
Samar Fouda (3904882)
Rana Fouda (3904885)
Ammar AlSafadi (3904888)

April 2017

Shows the authorsâ judgements for risk of bias assessment domains with supporting reasons. (DOCX 2...

Additional file 2: of Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis

Myrlene Aigbogun (6413417)
Robert Stellhorn (6413420)
Ann Hartry (5165477)
Ross Baker (1304541)
Howard Fillit (5165483)

March 2019

TableS2. All medications including antipsychotics and anti-dementia treatments collected for patient...

Additional file 2: of Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders

Gaurav Kaushik (1309584)
Yu Xia (8822)
Luobin Yang (3564683)
Michael Thomas (377350)

June 2016

Complete data of gene sets analyzed. Excel file containing a complete data of all gene sets (neurona...

Additional file 1: of Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia

Stanley Caroff (5783888)
Fan Mu (5783894)
Rajeev Ayyagari (829202)
Traci Schilling (5783900)
Victor Abler (4810095)
Benjamin Carroll (5783903)

September 2018

Table S1. Diagnostic Codes for Schizophrenia and Psychiatric Relapse. Listing of ICD-9 and ICD-10 co...

Additional file 2: of A cognitive forcing tool to mitigate cognitive bias â a randomised control trial

Eoin OâSullivan (6188645)
Susie Schofield (3567665)

January 2019

The clinical scenarios. Clinical vignettes designed to increase the chance of specific cognitive bia...

Additional file 1: of Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria

Brittany Dennis (3486200)
Pavel Roshanov (3486203)
Leen Naji (3486209)
Monica Bawor (516749)
James Paul (219464)
Carolyn Plater (3486206)
Guillaume Pare (3486221)
Andrew Worster (3486215)
Michael Varenbut (3486212)
Jeff Daiter (3486218)
David Marsh (203655)
Dipika Desai (347048)
Zainab Samaan (516751)
Lehana Thabane (17078)

October 2015

Table outlining description of studies included in the systematic review. (PDF 262 kb

Additional file 2: of Optimising first- and second-line treatment strategies for untreated major depressive disorder â the SUNâşD study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

Tadashi Kato (1538845)
Toshi Furukawa (5500829)
Akio Mantani (5500817)
Kenâichi Kurata (5500892)
Hajime Kubouchi (5500811)
Susumu Hirota (5500796)
Hirotoshi Sato (117839)
Kazuyuki Sugishita (5500823)
Bun Chino (5500832)
Kahori Itoh (5500826)
Yoshio Ikeda (260838)
Yoshihiro Shinagawa (5500805)
Masaki Kondo (197045)
Yasumasa Okamoto (82701)
Hirokazu Fujita (5500799)
Motomu Suga (219637)
Shingo Yasumoto (5500814)
Naohisa Tsujino (5500802)
Takeshi Inoue (208656)
Noboru Fujise (3164064)
Tatsuo Akechi (417303)
Mitsuhiko Yamada (113758)
Shinji Shimodera (306974)
Norio Watanabe (39913)
Masatoshi Inagaki (553137)
Kazuhira Miki (5500808)
Yusuke Ogawa (5500835)
Nozomi Takeshima (4433596)
Yu Hayasaka (4433599)
Aran Tajika (5500793)
Kiyomi Shinohara (4433602)
Naohiro Yonemoto (468815)
Shiro Tanaka (307051)
Qi Zhou (7408)
Gordon Guyatt (56595)

July 2018

Figure S1. Schedule of the assessments. Table S1. Incidence of suicidality, manic switches or any se...

Additional file 1: of Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study

Zheng Tong (668206)
Fangzhou Li (3707971)
Yusuke Ogawa (5500835)
Norio Watanabe (39913)
Toshi Furukawa (5500829)

November 2018

Appendix 1 Free text words for searching. Appendix 2 Tool for assessing risk of bias. Appendix 3 Tel...

Additional file 2: of Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Abstract

Extracted data

Additional file 2: of Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Abstract

Extracted data

Related items

Related items